We recently compiled a list of the 10 Best Up and Coming Stocks To Buy According to Analysts. In this article, we are going ...

Samer A. Al’Hadidi, MD, discusses factors influencing early use of chimeric antigen receptor T-cell therapy in patients with ...

$传奇生物(LEGN)$CARVYKTI 在瑞士上市，我很高兴地宣布 Swissmedic 刚刚将标签扩展更新为三线加治疗。瑞士是继美国、德国、奥地利和巴西之后，CARVYKTI目前向患者商业化的第五个国家。 FDA 将在明年上半年批准诺华在新泽西州的工厂开始商业生产。 EMA 实际上并不监管 CAR-T 的生产能力。这与美国 FDA 的政策不同。明年，当我们预计我们在比利时的 Tech Lane ...

The US Food and Drug Administration (FDA) is expected to make a Prescription Drug User Fee Act (PDUFA) decision by mid-2025.

With their push to end smoking in Atlantic City's casinos going nowhere fast in either the courts or the state Legislature, casino workers and supporters of smoke-free gambling halls demonstrated ...

The study compared CARVYKTI's efficacy and safety against standard-of-care regimens in patients with multiple myeloma.

We recently compiled a list of the 12 NASDAQ Stocks with Biggest Upside Potential According to Analysts. In this article, we ...

Johnson & Johnson (JNJ) said that Health Canada has issued a Notice of Compliance for CARVYKTI (ciltacabtagene autoleucel) for the ...

Authorization is based on results from the Phase 3 CARTITUDE-4 (MMY3002) study, which showed treatment with CARVYKTI® reduced the risk of disease progression or death by 74 per cent compared to ...

We recently compiled a list of the 10 Worst Performing Biotech Stocks in 2024. In this article, we are going to take a look ...

Santhosh K. Sadashiv, MD, discusses the role of chimeric antigen receptor T-cell therapy in patients with multiple myeloma.

Johnson & Johnson to showcase strength of its broad hematology portfolio and pipeline at the 2024 American Society of Hematology Annual Meeting ...